Source: Journal of Clinical Oncology. Unidade: EEL
Subjects: NEOPLASIAS, TUMOR CARCINOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARAUJO, ROGERIO AGENOR DE et al. EGF (epidermal growth factor) receptor expression in blood: Prognostic biomarker in overall survival (OS) of patients with non-metastatic triple negative (TN) breast carcinoma. Journal of Clinical Oncology, v. 37, n. 15, p. e14518-e14518, 2019Tradução . . Disponível em: https://doi.org/10.1200/jco.2019.37.15_suppl.e14518. Acesso em: 13 jun. 2024.APA
ARAUJO, R. O. G. E. R. I. O. A. G. E. N. O. R. D. E., ARAÚJO, B. R. E. N. O. J. E. H. A., Silva, M. J. B., Bernardino Neto, M., LUZ, F. E. L. I. P. E. A. N. D. R. É. S. C. O. R. D. E. R. O., DO AMARAL, P. E. D. R. O. A. U. G. U. S. T. O., et al. (2019). EGF (epidermal growth factor) receptor expression in blood: Prognostic biomarker in overall survival (OS) of patients with non-metastatic triple negative (TN) breast carcinoma. Journal of Clinical Oncology, 37( 15), e14518-e14518. doi:10.1200/jco.2019.37.15_suppl.e14518NLM
ARAUJO ROGERIOAGENORDE, ARAÚJO BRENOJEHA, Silva MJB, Bernardino Neto M, LUZ FELIPEANDRÉSCORDERO, DO AMARAL PEDROAUGUSTO, MARINHO EDUARDADACOSTA, NASCIMENTO CAMILAPIQUI, MOSCA ETELVINAROCHA, DELFINO PATRICIAFERREIRARIBEIRO, ANTONIOLI RAFAELMATHIAS, MENDES THAISREZENDE. EGF (epidermal growth factor) receptor expression in blood: Prognostic biomarker in overall survival (OS) of patients with non-metastatic triple negative (TN) breast carcinoma. [Internet]. Journal of Clinical Oncology. 2019 ;37( 15): e14518-e14518.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1200/jco.2019.37.15_suppl.e14518Vancouver
ARAUJO ROGERIOAGENORDE, ARAÚJO BRENOJEHA, Silva MJB, Bernardino Neto M, LUZ FELIPEANDRÉSCORDERO, DO AMARAL PEDROAUGUSTO, MARINHO EDUARDADACOSTA, NASCIMENTO CAMILAPIQUI, MOSCA ETELVINAROCHA, DELFINO PATRICIAFERREIRARIBEIRO, ANTONIOLI RAFAELMATHIAS, MENDES THAISREZENDE. EGF (epidermal growth factor) receptor expression in blood: Prognostic biomarker in overall survival (OS) of patients with non-metastatic triple negative (TN) breast carcinoma. [Internet]. Journal of Clinical Oncology. 2019 ;37( 15): e14518-e14518.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1200/jco.2019.37.15_suppl.e14518